Skip to main content

Table 1 Clinical and pathological characteristics of patients with HBV-related diseases

From: The signature of HBV-related liver disease in peripheral blood mononuclear cell DNA methylation

Variable CHB (n = 24) LC (n = 14) DLC( n = 10) P value
Age (mean ± SD) 42.5 ± 6.4 43.1 ± 7.2 41.3 ± 10.0 0.848
Gender     0.953
 Male/female 16 (66.7%)/8 10 (71.4%)/4 7 (70.0%)/3  
Smoking     0.181
 No 12 (50%) 5 (35.7%) 4 (40.0%)  
 Infrequent 7 2 3  
 Heavy 5 7 3  
Alcohol     
 No 15 (62.5%) 9 (64.3%) 8 (80.0%) 0.181
 Infrequent 7 1 2  
 Heavy 2 4 0  
TBIL (μmol/L) 25.63 ± 25.87 41.75 ± 46.23 70.04 ± 105.96 0.133
AST (U/L) 127.76 ± 182.01 332.8 ± 576.45 76.2 ± 103.7 0.131
ALT ((U/L)) 206.03 ± 319.22 524.14 ± 956.423 73.09 ± 117.38 0.130
APRI (mean ± SD) 77.75 ± 109.58 269.08 ± 475.83 91.53 ± 71.21 0.108
FIB4 (mean ± SD) 2.15 ± 1.42 3.63 ± 4.54 4.95 ± 3.31 0.054
HBsAg positive/negative 23 (100%)/0 (a) 12 (85.7%)/2 9 (100%)/0 (b) 0.083
Anti-HBs positive/negative 1 (4.16%)/22 2 (14.29%)/12 0 (0%)/9 0.291
HBeAg positive/negative 16 (69.56%)/7 6 (45.85%)/8 2 (22.22%)/7 0.034
Anti-HBe positive/negative 10 (43.47)/13 8 (57.14)/6 6 (66.67%)/3 0.447
Anti-HBc positive/negative 23 (100%)/0 14 (100%)/0 9 (100%)/0 NA
Fibrosis
 S1 10    
 S2 9    
 S3 5    
 S3-4   4   
 S4   10 10  
  1. CHB chronic hepatitis B, LC compensated liver cirrhosis, DLC decompensated liver cirrhosis, TBIL total bilirubin, AST aspartate transaminase, ALT alanine transaminase, APRI, FIB-4 serological diagnosis model, HBsAg hepatitis B surface antigen, Anti-HBs hepatitis B surface antibody, HBeAg hepatitis B e antigen, Anti-HBe hepatitis B e antibody, Anti-HBc hepatitis B core antibody. a: one CHB patient data of HBV markers unavailable, b: one DLC patient data of HBV markers unavailable